Wanbangde Pharmaceutical Holding Group Past Earnings Performance
Past criteria checks 1/6
Wanbangde Pharmaceutical Holding Group's earnings have been declining at an average annual rate of -35.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 49.8% per year. Wanbangde Pharmaceutical Holding Group's return on equity is 2.6%, and it has net margins of 6.4%.
Key information
-35.6%
Earnings growth rate
-38.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -49.8% |
| Return on equity | 2.6% |
| Net Margin | 6.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Wanbangde Pharmaceutical Holding Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,599 | 102 | 454 | 57 |
| 30 Jun 24 | 1,556 | 55 | 484 | 54 |
| 31 Mar 24 | 1,586 | 51 | 479 | 53 |
| 31 Dec 23 | 1,542 | 49 | 482 | 54 |
| 30 Sep 23 | 1,621 | -61 | 584 | 54 |
| 30 Jun 23 | 1,794 | 67 | 623 | 58 |
| 31 Mar 23 | 1,839 | 96 | 622 | 59 |
| 01 Jan 23 | 1,786 | 93 | 619 | 59 |
| 30 Sep 22 | 1,818 | 162 | 654 | 70 |
| 30 Jun 22 | 1,733 | 112 | 562 | 72 |
| 31 Mar 22 | 1,681 | 164 | 607 | 69 |
| 01 Jan 22 | 1,931 | 167 | 624 | 76 |
| 30 Sep 21 | 3,787 | 316 | 571 | 108 |
| 30 Jun 21 | 7,935 | 277 | 664 | 149 |
| 31 Mar 21 | 11,723 | 265 | 694 | 182 |
| 31 Dec 20 | 13,702 | 285 | 692 | 185 |
| 30 Sep 20 | 15,432 | 230 | 796 | 170 |
| 30 Jun 20 | 15,170 | 284 | 716 | 157 |
| 31 Mar 20 | 15,839 | 298 | 688 | 160 |
| 31 Dec 19 | 16,691 | 295 | 695 | 163 |
| 30 Sep 19 | 3,133 | 296 | 582 | 95 |
| 30 Jun 19 | 2,517 | 259 | 504 | 84 |
| 31 Mar 19 | 1,437 | 198 | 409 | 61 |
| 31 Dec 18 | 736 | 162 | 313 | 46 |
| 30 Sep 18 | 14,804 | 89 | 220 | 69 |
| 30 Jun 18 | 15,203 | 103 | 174 | 60 |
| 31 Mar 18 | 14,637 | 100 | 139 | 36 |
| 31 Dec 17 | 14,635 | 98 | 119 | 22 |
| 30 Sep 17 | 13,112 | 74 | 71 | 25 |
| 30 Jun 17 | 11,360 | 61 | 82 | 0 |
| 31 Mar 17 | 10,114 | 68 | 87 | 0 |
| 31 Dec 16 | 9,183 | 70 | 88 | 0 |
| 30 Sep 16 | 9,262 | 49 | 92 | 0 |
| 30 Jun 16 | 10,485 | 53 | 97 | 0 |
| 31 Mar 16 | 11,349 | 62 | 98 | 0 |
| 31 Dec 15 | 11,572 | 63 | 94 | 0 |
| 30 Sep 15 | 11,227 | 101 | 104 | 0 |
| 30 Jun 15 | 10,833 | 101 | 118 | 0 |
| 31 Mar 15 | 11,003 | 97 | 127 | 0 |
| 31 Dec 14 | 11,452 | 108 | 130 | 0 |
| 30 Sep 14 | 11,747 | 115 | 136 | 0 |
| 30 Jun 14 | 11,498 | 115 | 121 | 0 |
| 31 Mar 14 | 11,434 | 117 | 114 | 0 |
| 31 Dec 13 | 11,786 | 112 | 113 | 0 |
Quality Earnings: 002082 has a large one-off gain of CN¥61.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 002082 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002082's earnings have declined by 35.6% per year over the past 5 years.
Accelerating Growth: 002082 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002082 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 002082's Return on Equity (2.6%) is considered low.